Role of percutaneous left atrial appendage occlusion in stroke prevention for nonvalvular atrial fibrillation

doi:10.3969/j.issn.1004-583X.2016.01.003

Abstract

Abstract: Thromboembolism is the most serious complication in patients with atrial fibrillation(AF).It is crucial to predict and reduce the thromboembolic risk as soon as possible.Chronic anticoagulaion therapy has certain limitations in the prevention of thromboembolic events.Left atrial appendage(LAA) was confirmed as the main part of thrombus formation in patients with nonvalvular AF.As a result,percutaneous LAA occlusion has been advocated as a strategy for the prevention of thromboembolic event.LAA occlusion can effectively reduce the incidence of thromboembolic events in patients with nonvalvular AF and was also considered for patients with contraindications to oral anticoagulation.The WATCHMAN and ACP device have been authorized to enter the European Union market.LARIAT ligation device was also approved by US Food and Drug Administration because of its efficacy and safety.Due to its wide indications and high safety,percutaneous LAA occlusion or suture ligation is expected to become a reasonable alternative to prevent thromboembolic events for most patients with AF.

Key words: atrial fibrillation, thromboembolism, percutaneous left atrial appendage transcatheter occlusion

CLC Number:

R541.75

Qi Shuyuan,Tian Ying. Role of percutaneous left atrial appendage occlusion in stroke prevention for nonvalvular atrial fibrillation[J]. Clinical Focus, 2016, 31(1): 10-13.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.01.003

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I1/10

References

[1] Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study[J]. Circulation, 2004,110(9):1042-1046.
[2] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study[J]. Stroke, 1991,22(8):983-988.
[3] Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study[J]. Stroke, 1996,27(10):1760-1764.
[4] Garcia DA, Hylek E. Reducing the risk for stroke in patients who have atrial fibrillation[J]. Cardiol Clin, 2008,26(2):267-275.
[5] 徐荣,郭金城,郭明.老年心房颤动患者华法林长期抗凝治疗的效果与安全性[J].临床荟萃,2015,30(3):272-275.
[6] 王全河,杨国杰,吴楠.老年非瓣膜病性心房颤动患者华法林钠抗凝疗效及安全性研究[J].临床荟萃,2009,24 (5):399-401.
[7] Blackshear JL,Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation[J]. Ann Thorac Surg, 1996,61(2):755-759.
[8] Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience[J]. Circulation, 2002,105(16):1887-1889.
[9] Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials[J]. J Am Coll Cardiol, 2005,46(1):9-14.
[10] Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study[J]. JACC Cardiovasc Interv, 2009,2(7):594-600.
[11] Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation[J]. J Am Coll Cardiol, 2007,49(13):1490-1495.
[12] Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial[J]. Lancet, 2009,374(9689):534-542.
[13] Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry[J]. Circulation, 2011,123(4):417-424.
[14] Holmes DJ, Kar S, Price MJ, et al.Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial[J]. J Am Coll Cardio, 2014, 64(1):1-12.
[15] Holmes DJ, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis[J]. J Am Coll Cardio, 2015, 65(24):2614-2623.
[16] Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)[J]. J Am Coll Cardiol, 2013,61(25):2551-2556.
[17] Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience[J]. Catheter Cardiovasc Interv, 2011,77(5):700-706.
[18] Lam YY, Yip GW, Yu CM, et al. Left atrial appendage closure with AMPLATZER cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience[J]. Catheter Cardiovasc Interv, 2012,79(5):794-800.
[19] Danna P, Proietti R, Sagone A, et al. Does left atrial appendage closure with a cardiac plug system reduce the stroke risk in nonvalvular atrial fibrillation patients? A single-center case series[J]. Pacing Clin Electrophysiol, 2013,36(3):347-353.
[20] Lam YY, Yan BP, Doshi SK, et al. Preclinical evaluation of a new left atrial appendage occluder (Lifetech LAmbre device) in a canine model[J]. Int J Cardiol, 2013,168(4):3996-4001.
[21] Lee RJ, Bartus K, Yakubov SJ. Catheter-based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA: initial experience in a canine model[J]. Circ Cardiovasc Interv, 2010,3(3):224-229.
[22] Bartus K, Bednarek J, Myc J, et al. Feasibility of closed-chest ligation of the left atrial appendage in humans[J]. Heart Rhythm, 2011,8(2):188-193.
[23] Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience[J]. J Am Coll Cardiol, 2013,62(2):108-118.
[24] Pillarisetti J, Reddy YM, Gunda S, et al. Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: Understanding the differences in the location and type of leaks and their clinical implications[J]. Heart Rhythm,2015,12(7):1501-1507.
[25] Calvo N,Salterain N,Arguedas H,et al. Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation[J]. Europace, 2015,17(10):1533-1540.